Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?

We describe a patient who developed Corynebacterium striatum native valve endocarditis after receiving two 6-week courses of daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. The organism exhibited in vitro heteroresistance to daptomycin, with...

Full description

Autores:: Tran, Truc T.
Jaijakul, Siraya
Lewis, Cole T.
Diaz, Lorena
panesso, diana
Kaplan, Heidi B.
Beral, Valerie
Wanger, Audrey R.
Arias, César A.

Tipo de recurso:: Article of journal

Fecha de publicación:: 2012

Institución:: Universidad El Bosque

Repositorio:: Repositorio U. El Bosque

Idioma:: eng

id	UNBOSQUE2_485285121da478d75793554d5205a2e3
oai_identifier_str	oai:repositorio.unbosque.edu.co:20.500.12495/3644
network_acronym_str	UNBOSQUE2
network_name_str	Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
dc.title.translated.spa.fl_str_mv	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
title	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
spellingShingle	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Cefotaxima Staphylococcus aureus resistente a la meticilina Antibacterianos
title_short	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
title_full	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
title_fullStr	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
title_full_unstemmed	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
title_sort	Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?
dc.creator.fl_str_mv	Tran, Truc T. Jaijakul, Siraya Lewis, Cole T. Diaz, Lorena panesso, diana Kaplan, Heidi B. Beral, Valerie Wanger, Audrey R. Arias, César A.
dc.contributor.author.none.fl_str_mv	Tran, Truc T. Jaijakul, Siraya Lewis, Cole T. Diaz, Lorena panesso, diana Kaplan, Heidi B. Beral, Valerie Wanger, Audrey R. Arias, César A.
dc.contributor.orcid.none.fl_str_mv	Panesso, Diana [0000-0002-4049-9702]
dc.subject.decs.spa.fl_str_mv	Cefotaxima Staphylococcus aureus resistente a la meticilina Antibacterianos
topic	Cefotaxima Staphylococcus aureus resistente a la meticilina Antibacterianos
description	We describe a patient who developed Corynebacterium striatum native valve endocarditis after receiving two 6-week courses of daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. The organism exhibited in vitro heteroresistance to daptomycin, with two subpopulations showing daptomycin susceptibility (MIC of ≤0.094 μg/ml) and high-level resistance to daptomycin (MIC of ≥256 μg/ml). The selection of daptomycin-resistant Gram-positive skin flora with the potential of causing invasive disease may be a concern during prolonged courses of daptomycin.
publishDate	2012
dc.date.issued.none.fl_str_mv	2012
dc.date.accessioned.none.fl_str_mv	2020-07-31T22:47:06Z
dc.date.available.none.fl_str_mv	2020-07-31T22:47:06Z
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv	Artículo de revista
dc.type.coar.none.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
format	http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv	1098-6596
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/20.500.12495/3644
dc.identifier.doi.none.fl_str_mv	http://dx.doi.org/10.1128/AAC.00046-12
dc.identifier.instname.spa.fl_str_mv	instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv	https://repositorio.unbosque.edu.co
identifier_str_mv	1098-6596 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque
url	http://hdl.handle.net/20.500.12495/3644 http://dx.doi.org/10.1128/AAC.00046-12 https://repositorio.unbosque.edu.co
dc.language.iso.none.fl_str_mv	eng
language	eng
dc.relation.ispartofseries.spa.fl_str_mv	Antimicrobial agents and chemotherapy, 1098-6596, Vol. 56, Nro. 6, 2012, p. 3461-3464
dc.relation.uri.none.fl_str_mv	https://aac.asm.org/content/56/6/3461
dc.rights.local.spa.fl_str_mv	Acceso abierto
dc.rights.accessrights.none.fl_str_mv	http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess Acceso abierto
dc.rights.creativecommons.none.fl_str_mv	2012-03-26
rights_invalid_str_mv	Acceso abierto http://purl.org/coar/access_right/c_abf2 2012-03-26
eu_rights_str_mv	openAccess
dc.format.mimetype.none.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	American Society for Microbiology
dc.publisher.journal.spa.fl_str_mv	Antimicrobial agents and chemotherapy
institution	Universidad El Bosque
bitstream.url.fl_str_mv	https://repositorio.unbosque.edu.co/bitstreams/a587a53f-6eba-4130-8e07-76c05bca815d/download https://repositorio.unbosque.edu.co/bitstreams/0ba35791-afff-4cc7-84cd-96bd491cf21a/download https://repositorio.unbosque.edu.co/bitstreams/a85af7fc-85d4-4cfb-a137-d8bf725a55a6/download https://repositorio.unbosque.edu.co/bitstreams/2c1e493c-5f63-469e-a851-8c308560467b/download
bitstream.checksum.fl_str_mv	41d1afcfe66668f766ec4862317e8fb2 8a4605be74aa9ea9d79846c1fba20a33 c77f8c0b8453d24aaacccf7afff3ded3 9c92e08f30c0d19f5a38c815fff8b6c2
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv	bibliotecas@biteca.com
_version_	1808397393577639936
spelling	Tran, Truc T.Jaijakul, SirayaLewis, Cole T.Diaz, Lorenapanesso, dianaKaplan, Heidi B.Beral, ValerieWanger, Audrey R.Arias, César A.Panesso, Diana [0000-0002-4049-9702]2020-07-31T22:47:06Z2020-07-31T22:47:06Z20121098-6596http://hdl.handle.net/20.500.12495/3644http://dx.doi.org/10.1128/AAC.00046-12instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coapplication/pdfengAmerican Society for MicrobiologyAntimicrobial agents and chemotherapyAntimicrobial agents and chemotherapy, 1098-6596, Vol. 56, Nro. 6, 2012, p. 3461-3464https://aac.asm.org/content/56/6/3461Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?Artículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85CefotaximaStaphylococcus aureus resistente a la meticilinaAntibacterianosWe describe a patient who developed Corynebacterium striatum native valve endocarditis after receiving two 6-week courses of daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. The organism exhibited in vitro heteroresistance to daptomycin, with two subpopulations showing daptomycin susceptibility (MIC of ≤0.094 μg/ml) and high-level resistance to daptomycin (MIC of ≥256 μg/ml). The selection of daptomycin-resistant Gram-positive skin flora with the potential of causing invasive disease may be a concern during prolonged courses of daptomycin.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2012-03-26ORIGINALTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdfTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdfapplication/pdf516718https://repositorio.unbosque.edu.co/bitstreams/a587a53f-6eba-4130-8e07-76c05bca815d/download41d1afcfe66668f766ec4862317e8fb2MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/0ba35791-afff-4cc7-84cd-96bd491cf21a/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdf.jpgTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdf.jpgIM Thumbnailimage/jpeg10025https://repositorio.unbosque.edu.co/bitstreams/a85af7fc-85d4-4cfb-a137-d8bf725a55a6/downloadc77f8c0b8453d24aaacccf7afff3ded3MD53TEXTTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdf.txtTruc T. Tran, Siraya Jaijakul, Cole T. Lewis, Lorena Diaz, _2012.pdf.txtExtracted texttext/plain18258https://repositorio.unbosque.edu.co/bitstreams/2c1e493c-5f63-469e-a851-8c308560467b/download9c92e08f30c0d19f5a38c815fff8b6c2MD5420.500.12495/3644oai:repositorio.unbosque.edu.co:20.500.12495/36442024-02-06 23:00:58.842open.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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

Native valve endocarditis caused by corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?

Publicaciones similares